Emerging perspectives in the combined application of SGLT2i and GLP-1 RAs for CKD and DKD, highlighting advances in biomarker discovery, personalized treatment strategies, and novel therapeutic indications are depicted in Figure 6. This evidence concerns the gene GCG and chronic kidney disease.